Home › Funds › Ikarian Capital, LLC › SLS

Ikarian Capital, LLC position in SLS

SELLAS LIFE SCIENCES GROUP I · Health Care

Ikarian Capital, LLC reported holding 354,700 shares of SLS (SELLAS LIFE SCIENCES GROUP I) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.64% of its reported portfolio and ranking #42 among its reported holdings. Ikarian Capital, LLC has disclosed SLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)354.70K sh
Reported value held$4.37M
Portfolio Weight0.64%
First reportedQ2 2026
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Ikarian Capital, LLC's SLS position evolved

Ikarian Capital, LLC first disclosed a stake in SLS in Q2 2026 at 354,700 shares (US$5.2M). Across 2 filings, Ikarian Capital, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 354,700 shares valued at US$4.4M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 354.70K $5.24M New
Q3 2026 354.70K $4.37M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SLS and 13F data

SLS (SELLAS LIFE SCIENCES GROUP I) is a Health Care company. 96 other funds we track also report a position in SLS — the largest reported positions include Anson Funds Management LP (US$38.2M), PERCEPTIVE ADVISORS LLC (US$30.8M), DAGCO, INC. (US$16.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SLS

All SLS fund holders →

FAQ

How long has Ikarian Capital, LLC held SLS?

Ikarian Capital, LLC has disclosed SLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Ikarian Capital, LLC's current position in SLS?

As of Q3 2026, Ikarian Capital, LLC holds 354.70K shares of SLS (SELLAS LIFE SCIENCES GROUP I), valued at $4.37M, representing 0.64% of its reported portfolio and ranking #42.

Has Ikarian Capital, LLC been buying or selling SLS?

In the latest 13F filing (Q3 2026), Ikarian Capital, LLC held unchanged its position in SLS.

Which other funds hold SLS?

Other major institutional holders of SLS include Anson Funds Management LP, PERCEPTIVE ADVISORS LLC, DAGCO, INC., among 96 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.